Iptakalim ameliorates monocrotaline-induced pulmonary arterial hypertension in rats

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 1, 2013, Pages 60-69

  Li, Junshan ^a,b   Long, Chaoliang ^a   Cui, Wenyu ^a   Wang, Hai ^a,c  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b 309TH HOSPITAL OF PLA   (China)

^c Thadweik Academy of Medicine   (China)

Author keywords

ATP sensitive potassium channel opener; iptakalim; monocrotaline; pulmonary arterial hypertension

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1; IPTAKALIM; MONOCROTALINE; NITRIC OXIDE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HEART; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART RATE; HEART RIGHT VENTRICLE; HEART VENTRICLE SEPTUM; HISTOLOGY; LUNG PARENCHYMA; MALE; MEAN ARTERIAL PRESSURE; MOLECULAR DYNAMICS; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ENDOTHELIN-1; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; KATP CHANNELS; LUNG; MALE; MONOCROTALINE; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE; PROPYLAMINES; RATS; RATS, WISTAR;

EID: 84871556857     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248412458154     Document Type: Article

References (44)

1. Schannwell CM, Steiner S, Strauer BE. Diagnostics in pulmonary hypertension. J Physiol Pharmacol. 2007 ; 58 (suppl 5 pt 2). 591-602
2. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 ; 30 (20). 2493-2537
3. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009 ; 30 (4). 394-403
4. Crosswhite P, Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens. 2010 ; 28 (2). 201-212
5. Böhm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007 ; 76 (1). 8-18
6. Csiszar A, Labinskyy N, Olson S, et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 2009 ; 54 (3). 668-675
7. Hironaka E, Hongo M, Sakai A, et al. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res. 2003 ; 60 (3). 692-699
8. Firth AL, Mandel J, Yuan JX. Idiopathic pulmonary arterial hypertension. Dis Model Mech. 2010 ; 3 (5-6). 268-273
9. Wang H, Tang Y, Wang L, Long CL, Zhang YL. ATP-sensitive potassium channel openers and 2,3-dimethyl-2-butylamine derivatives. Curr Med Chem. 2007 ; 14 (2). 133-155
10. Long CL, Qin XC, Pan ZY, et al. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. J Hypertens. 2008 ; 26 (12). 2326-2338
11. Tang Y, Long CL, Wang RH, Cui W, Wang H. Activation of SUR2B/Kir6.1 subtype of adenosine triphosphate-sensitive potassium channel improves pressure overload induced cardiac remodeling via protecting endothelial function. J Cardiovasc Pharmacol. 2010 ; 56 (4). 345-353
12. Wang H, Long CL, Zhang YL. A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension. J Pharmacol Exp Ther. 2005 ; 312 (3). 1326-1333
13. Pan Z, Huang J, Cui W, Long C, Zhang Y, Wang H. Targeting hypertension with a new ATP sensitive potassium channel opener iptakalim. J Cardiovasc Pharmacol. 2010 ; 56 (3). 215-228
14. Pharmacological characteristics of the novel antihypertensive drug, iptakalim hydrochloride, and its molecular mechanisms. Drug Dev Res. 2003 ; 58: 65-68
15. Gao S, Long CL, Wang RH, Wang H. KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res. 2009 ; 83 (3). 444-456
16. Xie WP, Wang H, Wang H, Hu G. Effects of iptakalim hydrochloride, a novel KATP channel opener, on pulmonary vascular remodeling in hypoxic rats. Life Sci. 2004 ; 75 (17). 2065-2076
17. Xie W, Wang H, Ding J, Wang H, Hu G.. Anti-proliferating effect of iptakalim, a novel KATP channel opener, in cultured rabbit pulmonary arterial smooth muscle cells. Eur J Pharmacol. 2005 ; 511 (2-3). 81-87
18. Zhu Y, Zhang S, Xie W, Li Q, Zhou Y, Wang H. Iptakalim inhibited endothelin-1-induced proliferation of human pulmonary arterial smooth muscle cells through the activation of KATP channel. Vasc Pharmacol. 2008 ; 48 (2-3). 92-99
19. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009 ; 297 (6). L1013 - L1032
20. Naeije R, Dewachter L. Animal models of pulmonary arterial hypertension. Rev Mal Respir. 2007 ; 24 (4 pt 1). 481-496
21. Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003 ; 22 (2). 358-363
22. Prié S, Stewart DJ, Dupuis J. Endothelin A receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension. Circulation. 1998 ; 97 (21). 2169-2174
23. Homma N, Morio Y, Takahashi H, et al. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension. Respiration. 2006 ; 73 (1). 105-112
24. Sawamura F, Kato M, Fujita K, Nakazawa T, Beardsworth A. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. J Pharmacol Sci. 2009 ; 111 (3). 235-243
25. Minamino T, Hori M. Protecting endothelial function: a novel therapeutic target of ATP-sensitive potassium channel openers. Cardiovasc Res. 2007 ; 73 (3). 448-449
26. Wang H, Long C, Duan Z, Shi C, Jia G, Zhang Y. A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells. Cardiovasc Res. 2007 ; 73 (3). 497-503
27. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007 ; 50 (25). 2357-2368
28. Woodard Ge, Rosado JA.. Recent advances in natriuretic peptide research. J Cell Mol Med. 2007 ; 11 (6). 1263-1271
29. Speyer CL, Neff TA, Warner RL, et al. Regulatory effects of iNOS on acute lung inflammatory responses in mice. Am J Pathol. 2003 ; 163 (6). 2319-2328
30. Markovic N, McCaig LA, Stephen J, et al. Mediators released from LPS-challenged lungs induce inflammatory responses in liver vascular endothelial cells and neutrophilic leukocytes. Am J Physiol Gastrointest Liver Physiol. 2009 ; 297 (6). G1066 - G1076
31. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005 ; 111 (21). 2812-2819
32. Drexler H. Nitric oxide synthases in the failing human heart: a doubled-edged sword?. Circulation. 1999 ; 99 (23). 2972-2975
33. Smith JA, Radomski MW, Schulz R, Moncada S, Lewis MJ. Porcine ventricular endocardial cells in culture express the inducible form of nitric oxide synthase. Br J Pharmacol. 1993 ; 108 (4). 1107-1110
34. Schwartz D, Mendonca M, Schwartz I, et al. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest. 1997 ; 100 (2). 439-448
35. Campian ME, Verberne HJ, Hardziyenka M, et al. Serial noninvasive assessment of apoptosis during right ventricular disease progression in rats. J Nucl Med. 2009 ; 50 (8). 1371-1377
36. Ing DJ, Zang J, Dzau VJ, Webster KA, Bishopric NH. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res. 1999 ; 84 (1). 21-33
37. Eleuteri E, Magno F, Gnemmi I, et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front Biosci. 2009 ; 14: 2230-2237
38. Jurasz P, Courtman D, Babaie S, Stewart DJ. Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials. Pharmacol Ther. 2010 ; 126 (1). 1-8
39. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009 ; 54 (1 suppl). S10 - S19
40. Xia Z, Luo T, Liu HM, et al. L-arginine enhances nitrative stress and exacerbates tumor necrosis factor-alpha toxicity to human endothelial cells in culture: prevention by propofol. J Cardiovasc Pharmacol. 2010 ; 55 (4). 358-367
41. Jankov RP, Lewis P, Kantores C, et al. Peroxynitrite mediates right-ventricular dysfunction in nitric oxide-exposed juvenile rats. Free Radic Biol Med. 2010 ; 49 (9). 1453-1467
42. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004 ; 122 (4). 339-352
43. Ray R, Shah AM. NADPH oxidase and endothelial cell function. Clin Sci (Lond). 2005 ; 109 (3). 217-226
44. Redout EM, Wagner MJ, Zuidwijk MJ, et al. Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species. Cardiovasc Res. 2007 ; 75 (4). 770-781